Relay Therapeutics Is A Buy For Its Superb Safety Data (NASDAQ:RLAY)

Company Overview - Relay Therapeutics, Inc. is focused on precision oncology, specifically developing RLY-2608, an allosteric and pan-mutant PI3Kα inhibitor targeting breast cancer [1] - RLY-2608 is currently in phase 3 trials, indicating significant progress in its development [1] Investment Strategy - The company is associated with a Dubai-based investor who emphasizes building a resilient, income-generating portfolio with a long-term growth mindset [1] - The investment approach is primarily long-only, blending dividend-paying equities, REITs, and selective growth opportunities [1] - The investor prioritizes disciplined, fundamentals-driven investing, focusing on capital preservation while compounding returns over time [1]